Successful treatment of immune checkpoint inhibitor-associated fulminant myocarditis with abatacept and ruxolitinib: a case report
This case highlights ICI myocarditis refractory to corticosteroids leading to treatment with second-line immunosuppression. As immunotherapies are increasingly applied to a broader range of cancers, further research is needed to evaluate the optimal treatment strategy for ICI-related myocarditis and other immune-related adverse events.
Authors
- Javid J. Moslehi (ORCID: https://orcid.org/0000-0001-5443-4312)
- Richard Kar-Hang Cheng (ORCID: https://orcid.org/0000-0001-5994-5998)
- Elena Wadden (ORCID: https://orcid.org/0000-0002-6316-071X)
- Petros D. Grivas (ORCID: https://orcid.org/0000-0003-3965-3394)
- Andrew J. Portuguese (ORCID: https://orcid.org/0000-0003-1010-4578)
- Shailender Bhatia (ORCID: https://orcid.org/0000-0002-3816-2238)
- Joe‐Elie Salem (ORCID: https://orcid.org/0000-0002-0331-3307)
- Carol Lai
Institutions
- Inserm (FR)
- University of California, San Francisco (US)
- University of Washington (US)
- University of Washington Medical Center (US)
- Sorbonne Université (FR)
- Fred Hutch Cancer Center (US)
- Assistance Publique – Hôpitaux de Paris (FR)
- Straub Medical Center (US)
- Pitié-Salpêtrière Hospital (FR)
Publication Details
- Journal
- European Heart Journal - Case Reports
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1093/ehjcr/ytaf019
- Citations
- 7
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 7.32